Results 171 to 180 of about 246,720 (281)

Population Pharmacokinetics Analysis of Talazoparib and Enzalutamide Combination Therapy for Patients With Metastatic Castration‐Resistant Prostate Cancer

open access: yesThe Journal of Clinical Pharmacology, EarlyView.
Abstract The poly(ADP‐ribose) polymerase inhibitor talazoparib, combined with the androgen receptor inhibitor enzalutamide is approved for patients with homologous recombination repair (HRR) gene‐mutated metastatic castration‐resistant prostate cancer (mCRPC) in the US and with mCRPC in whom chemotherapy is not clinically indicated in Europe.
Mark Hadigol   +5 more
wiley   +1 more source

Identification of Natural and Artificial Modifications in DNA at the Nanometer Level

open access: yesJournal of Raman Spectroscopy, EarlyView.
Short single‐ and double‐stranded DNA sequences with natural and artificial markers are examined at ambient conditions using TERS to identify and localize the labelled nucleobases. The differences between single‐ and double‐stranded DNA should provide clear experimental evidence of the extreme surface sensitivity of TERS.
Tanja Deckert‐Gaudig   +4 more
wiley   +1 more source

Identification of mono-ADP-ribose readers using well-defined photoaffinity-based probes. [PDF]

open access: yesRSC Chem Biol
van der Heijden FLAM   +5 more
europepmc   +1 more source

Chewable Soft Gelatin Capsules: Design and Formulation Strategies for a Patient‐Preferred Dosage Alternative

open access: yesMacromolecular Materials and Engineering, EarlyView.
Chewable softgels are a patient‐preferred alternative to conventional oral forms, offering pleasant taste, fast onset, and suitability for children or patients with swallowing difficulties. However, they present relevant challenges in their formulation: the shell must balance chewability, machinability, and stability, while the fill must mask the ...
Almudena Naharros‐Molinero   +3 more
wiley   +1 more source

CRISPR Enabled Precision Oncology: From Gene Editing to Tumor Microenvironment Remodeling

open access: yesMed Research, EarlyView.
CRISPR technology has progressed from a prokaryotic immune system to a diverse suite of editing platforms, including Cas nucleases, base and prime editors, and RNA‐targeting enzymes. These advances enable precise genomic and epigenomic interventions, high‐throughput functional screening, and immune engineering.
Kailai Li   +8 more
wiley   +1 more source

Targeting MARylation and DePARylation in Cancer Therapy: New Promising Therapeutic Opportunities. [PDF]

open access: yesCancers (Basel)
Cabeza-Fernández V   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy